Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. | During its first full year ...
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...
Sanofi (SNY) on Thursday reported fourth-quarter earnings of $728.6 million. The company said it had net income of 29 cents per share. Earnings, adjusted for non-recurring costs and to account for ...
The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...
Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.
Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €114.00. The company’s shares closed last Tuesday at $105.85. Cespedes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback